Insulin sensitizer has anti-inflammatory effect in diabetics
A new study by University at Buffalo researchers found that insulin sensitizer rosiglitazone (Avandia) has a significant anti-inflammatory effect in Type 2 diabetes patients. The drug decreased levels of oxygen free radicals and inflammatory markers, reducing the risk of heart disease.